- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Cardio Diagnostics Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 29.10. | Bilfinger-CDIO Pfau macht Technologie zum Business-Treiber | 26 | CIO | ||
| 15.10. | Aktionäre von Cardio Diagnostics billigen Direktorenriege und Kapitalmaßnahmen | 17 | Investing.com Deutsch | ||
| CARDIO DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 15.10. | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.09. | Henkel befördert Frank Tenbrock zum CDIO | 35 | CIO | ||
| 14.08. | Cardio Diagnostics Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 22.07. | Cardio Diagnostics: Medicare gibt vorläufige Erstattungssätze für Herztests bekannt | 1 | Investing.com Deutsch | ||
| 22.07. | Medicare sets preliminary payment rates for Cardio Diagnostics tests | 1 | Investing.com | ||
| 08.07. | Studienkooperation mit AGEPHA Pharma treibt Aktie von Cardio Diagnostics an | - | Investing.com Deutsch | ||
| 18.06. | Medicover AB: Lukasz Krause new Chief Digital Information Officer (CDIO) Medicover | 305 | GlobeNewswire (Europe) | Lukasz Krause will assume the role of CDIO as of 1 July 2025 and be part of the executive management team of Medicover.
Lukasz brings a wealth of experience in IT management having successfully overseen... ► Artikel lesen | |
| 08.05. | Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split | 1.026 | Business Wire | CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. ("Cardio" or the "Company") (NASDAQ: CDIO), today announced a 1-for-30 reverse stock split of its common stock effective with the market opening... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,990 | -0,90 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| NURIX THERAPEUTICS | 18,840 | -0,89 % | Cathie Wood's ARK sells Iridium stock, buys Nurix on Wednesday | ||
| EDGEWISE THERAPEUTICS | 22,770 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 61,74 | -4,72 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,280 | -1,89 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 71,98 | +0,17 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| IMMUNOME | 23,460 | 0,00 % | Immunome prices public offering of common stock at $21.50 per share | ||
| OLEMA PHARMACEUTICALS | 34,250 | -4,41 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| MINERALYS THERAPEUTICS | 36,040 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| TREVI THERAPEUTICS | 12,410 | -1,59 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,180 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 41,370 | -0,43 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| BIONTECH | 78,60 | +0,13 % | Alarm bei Evotec! BioNTech und Vidac Pharma mit Erfolgen beim Kampf gegen Krebs! Analysten raten zum Kauf! | Bei Evotec läuten die Alarmglocken. Ein Großaktionär ist komplett beim deutschen Biotech-Unternehmen ausgestiegen. Dabei notiert das Wertpapier auf dem Niveau von 2016. Einen Meilenstein hat dagegen... ► Artikel lesen | |
| VOR BIOPHARMA | 15,860 | 0,00 % | Vor Bio raises $150 million in private placement to fund clinical trials | ||
| PRAXIS PRECISION MEDICINES | 274,81 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen |
CARDIO DIAGNOSTICS HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARDIO DIAGNOSTICS HOLDINGS INC finden Sie auf Wallstreet Online.